Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study to Investigate Patients' Prognosis and Patterns of Adjuvant Chemotherapy Use After Curative Resection of Primary Colon Cancer at High-risk Stage II or Stage III

NCT04416490 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT04416490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04416490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study to Investigate Patients' Prognosis and Patterns of Adjuvant Chemotherapy Use After Curative Resection of Primary Colon Cancer at High-risk Stage II or Stage III
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Phase
Observational
Overall status
Active, not recruiting
Start date
March 25, 2020
Completion date
February 28, 2027
Enrollment
2,013 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii colon cancer, stage iii colon cancer